Bioventus Inc.

Bioventus Inc.

BVS·NASDAQ

$8.55

+5.4%
HealthcareMedical - Devices

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

At a Glance

Live Snapshot
Market Cap$579.25M
EPS0.3400
P/E Ratio25.15
Earnings Date08/05/2026
10.79%
Return on Invested Capital
-650%
3Y-193.0%
5Y+113.0%
10Y-
12.35%
Return on Equity
-154%
3Y-125.0%
5Y+7.0%
10Y-
3.33%
Return on Assets
-172%
3Y-129.0%
5Y-
10Y-
Bioventus Inc.

Bioventus Inc. Management Team

BVS · NASDAQ
MR

Mr. Robert E. Claypoole

President, Chief Executive Officer & Director

Compensation

$2,759,410

Born 1972(Age 54)
male
MK

Ms. Katrina J. Church J.D.

Senior Vice President & Chief Compliance Officer

Born 1962(Age 64)
female
MM

Mr. Mark L. Singleton

Senior Vice President & Chief Financial Officer

Compensation

$983,601

Born 1970(Age 56)
male
MH

Ms. Helen Leupold

Senior Vice President & Chief Human Resources Officer

female
MD

Mr. Dave Venner

Senior Vice President & GM of Surgical

male
MM

Mr. Mike Crowe B.S., M.B.A.

Senior Vice President of Operations

male
MA

Mr. Anthony D'Adamio J.D.

Senior Vice President, General Counsel & Corporate Secretary

Compensation

$867,053

Born 1961(Age 65)
male
MD

Mr. David Crawford

Vice President of Investor Relations & Treasurer

male
bvs

Bioventus Inc. Insider Positioning

BVS · NASDAQ

During the last 12 months, insiders have sold $312K worth of BVS shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

12.0K

105.44K

Net Activity

-105K

-$105K

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

27.7K

206.91K

Net Activity

-207K

-$207K

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

1
MM

Mcmurry-Heath Michelle

Director

29.7K shares2 transactions

$237K

2
NGP

Nohra Guy P

Director

10.0K shares1 transactions

$76K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $312K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$105K

Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.

Insider Participation

High Selling

2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

Insider Activity Insight

Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.

SEC Filings

BVS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

April 22, 2026
December 31, 2025
2025
DEF 14A

DEF 14A 2024

N/A

April 22, 2025
December 31, 2024
2024
DEF 14A

DEF 14A 2024

N/A

April 26, 2024
June 11, 2024
2024
DEF 14A

DEF 14A 2023

N/A

April 27, 2023
June 07, 2023
2023
DEF 14A

DEF 14A 2022

N/A

April 29, 2022
June 17, 2022
2022
Showing 1 to 5 of 5 filings